Background

It is still unclear whether fentanyl directly alters left ventricular (LV) contractility and oxygen consumption. This is because of the difficulty in defining and evaluating contractility and energy use independently of ventricular loading conditions and heart rate in beating whole hearts.

Methods

This study was conducted to clarify the mechanoenergetic effects of intracoronary fentanyl in six excised cross-circulated canine hearts. The authors used the framework of the E(max) (a contractility index)-PVA (systolic pressure-volume area, a measure of total mechanical energy)-VO2 (myocardial oxygen consumption per beat) relationship practically independent of ventricular loading conditions. The authors measured LV pressure, volume, coronary flow, and arteriovenous oxygen content difference to calculate E(max), PVA, and VO2. They first obtained the VO2-PVA relationship for varied LV volumes at control E(max). The authors then obtained the VO2-PVA relationship at a constant LV volume, whereas coronary blood fentanyl concentration was increased in steps up to 240 ng/ml. Finally, they obtained the VO2-PVA relationship for varied LV volumes at the final dose of fentanyl.

Results

Fentanyl at any concentrations did not significantly change E(max), PVA, and VO2 from the control. The linear end-systolic pressure-volume relations and their slopes were virtually the same between the control and fentanyl volume loading in each heart. Further, either the slope (oxygen cost of PVA) or the VO2 intercept (unloaded VO2) of the linear VO2-PVA relationship remained unchanged by fentanyl.

Conclusions

These results indicate that intracoronary fentanyl produces virtually no effects on LV mechanoenergetics for a wide range of its blood concentration.

In recent clinical anesthesia, the high-dose fentanyl anesthesia technique is adopted to avoid noxious stimuli for the patients either undergoing cardiac surgery or with poor left ventricular (LV) function. [1–11] In these patients, an anesthetic should produce no adverse effects on cardiac mechanoenergetics for a wide safety range of blood anesthetic concentration.

Most clinical and laboratory studies indicated little change in cardiac function after administration of fentanyl (10–160 micro gram/kg) alone. [1–7,12–15] Some laboratory studies using isolated myocardium preparations indicated a marked negative inotropic effect of fentanyl at much higher concentrations than those achieved in clinical practice. [16,17] Thus, it is still controversial whether fentanyl depresses cardiac contractile function (contractility).

In contrast to numerous studies on the effects on cardiac function, few studies have reported on the effects of fentanyl on cardiac energetics. Fentanyl did not affect cardiac energetics and blood flow distribution in dogs. [12,18] Fentanyl was devoid of major direct effects on coronary circulation and myocardial metabolism in dogs, pigs, and rats. [19] However, fentanyl markedly reduced coronary sinus blood flow and cardiac oxygen consumption per minute accompanied by bradycardia, whereas blood pressure and the maximal rate of increase of LV pressure (LV dp/dtmax) remained unchanged in dogs. [13] Thus, it is not yet clear whether and to what extent fentanyl alters cardiac energetics and coronary circulation.

These contradictions may derive from the difficulty in defining and evaluating LV contractility and energy use in beating whole hearts independently of ventricular loading conditions and heart rate. [14]

We performed the present study to investigate whether intracoronary fentanyl produces any direct effects on LV mechanoenergetics in the excised (denervated) cross-circulated (blood-perfused) canine heart. To evaluate the cardiac inotropic effect of fentanyl, we used a reliable contractility index, Emax, practically independent of ventricular loading conditions. [20–24] To assess the effects of fentanyl on cardiac energetics, we used the relationship between VO2(myocardial oxygen consumption per beat) and PVA (systolic pressure-volume area, a measure of total mechanical energy) of the LV. [20–22,25–29]

Theoretical Background 

The framework of the Emax-PVA-VO2relationship has the following physiologic significance. Emaxis the maximal value of time-varying elastance and is determined as the maximal ratio of P(t)/[V(t)- V0]. [23] P(t) means instantaneous LV pressure; V(t) means instantaneous LV volume, and V0means the volume at which LV peak isovolumic pressure is zero. Emaxis alternatively defined as the slope (Ees) of the end-systolic pressure-volume relationship (ESPVR) in a stable contractile condition (Figure 1(A)). [24] Emaxsensitively reflects LV contractility, practically independent of ventricular pre- and afterloading conditions within their physiologic ranges. [20–24]

Figure 1. Schematic illustrations of the framework of the Emax(a contractility index)-PVA (systolic pressure volume area, a measure of total mechanical energy)-VO2(myocardial oxygen consumption per beat) relationship fully used in this study. A, Emaxand PVA in the left ventricular (LV) pressure-volume (P-V) diagram. Emaxis the slope of the line connecting the end-systolic P-V point and V0(see below). E sub max is alternatively defined as the slope (Ees) of the end-systolic pressure-volume relation (ESPVR) in a stable contractile state. PVA is the area surrounded by the ESPVR line, the end-diastolic P-V relation curve, and the systolic P-V trajectory. V0is a volume at which LV isovolumic peak pressure and, hence, PVA are zero. In an isovolumic contraction, P-V data points move up and down on the vertical systolic P-V trajectory as indicated by arrows, and PVA is composed only of potential energy. B, The linear VO2-PVA relationship in a volume loading run (see text) in a stable contractile state (thick solid line). The slope a of this relationship represents the oxygen cost of PVA. VO2consists of two components at the VO2intercept b of this relation: the PVA-dependent VO2corresponding to the energy use for crossbridge cycling, and the PVA-independent VO2(unloaded VO2) corresponding to the energy use for the total calcium handling in the excitation-contraction (E-C) coupling and for basal metabolism. C, Three volume loading VO2-PVA relationships in the baseline contractility (thick solid line) and in two altered contractilities (thin solid lines). They usually are parallel to each other, having the same oxygen cost of PVA (slope a). Only the PVA-independent VO2(b, indicated by arrows) increases or decreases as Emaxincreases or decreases, respectively. In an inotropism run at a constant LV volume, VO2-PVA data point (filled circle) deviating from a baseline data (empty circle) with changes in Emaxforms a new steeper relationship. This steeper VO2-PVA relationship is the composite VO2-PVA relationship (upward and downward relationships are shown as thick solid lines with arrow heads). D, The relationship between the PVA-independent VO2and Emax. The slope c of this relationship represents the oxygen cost of Emax, and the PVA-independent VO2intercept d indicates the PVA-independent VO2at zero Emaxnearly equal to basal metabolism.

Figure 1. Schematic illustrations of the framework of the Emax(a contractility index)-PVA (systolic pressure volume area, a measure of total mechanical energy)-VO2(myocardial oxygen consumption per beat) relationship fully used in this study. A, Emaxand PVA in the left ventricular (LV) pressure-volume (P-V) diagram. Emaxis the slope of the line connecting the end-systolic P-V point and V0(see below). E sub max is alternatively defined as the slope (Ees) of the end-systolic pressure-volume relation (ESPVR) in a stable contractile state. PVA is the area surrounded by the ESPVR line, the end-diastolic P-V relation curve, and the systolic P-V trajectory. V0is a volume at which LV isovolumic peak pressure and, hence, PVA are zero. In an isovolumic contraction, P-V data points move up and down on the vertical systolic P-V trajectory as indicated by arrows, and PVA is composed only of potential energy. B, The linear VO2-PVA relationship in a volume loading run (see text) in a stable contractile state (thick solid line). The slope a of this relationship represents the oxygen cost of PVA. VO2consists of two components at the VO2intercept b of this relation: the PVA-dependent VO2corresponding to the energy use for crossbridge cycling, and the PVA-independent VO2(unloaded VO2) corresponding to the energy use for the total calcium handling in the excitation-contraction (E-C) coupling and for basal metabolism. C, Three volume loading VO2-PVA relationships in the baseline contractility (thick solid line) and in two altered contractilities (thin solid lines). They usually are parallel to each other, having the same oxygen cost of PVA (slope a). Only the PVA-independent VO2(b, indicated by arrows) increases or decreases as Emaxincreases or decreases, respectively. In an inotropism run at a constant LV volume, VO2-PVA data point (filled circle) deviating from a baseline data (empty circle) with changes in Emaxforms a new steeper relationship. This steeper VO2-PVA relationship is the composite VO2-PVA relationship (upward and downward relationships are shown as thick solid lines with arrow heads). D, The relationship between the PVA-independent VO2and Emax. The slope c of this relationship represents the oxygen cost of Emax, and the PVA-independent VO2intercept d indicates the PVA-independent VO2at zero Emaxnearly equal to basal metabolism.

Close modal

Systolic pressure-volume area is a measure of total mechanical energy generated by an LV contraction. [20–22,25–31] In an isovolumic contraction, PVA is composed only of potential energy and is quantified by the area in the pressure-volume (P-V) diagram that is bounded by the ESPVR line, the end-diastolic P-V relationship curve, and the systolic P-V trajectory (Figure 1(A)). LV PVA closely and linearly correlates with LV VO2in a load-independent manner in a stable contractile state with a constant Emax(Figure 1(B)). [25–27] The slope (a) of the VO sub 2 -PVA relationship means the oxygen cost of PVA. [20–22,27,29] VO sub 2 can be divided into the PVA-dependent and the PVA-independent VO2(unloaded VO2) components at the VO2intercept (b) of the VO sub 2 -PVA relationship. The PVA-dependent VO2corresponds to the energy use for crossbridge cycling, and the PVA-independent VO2corresponds to the energy use for total calcium handling in the excitation-contraction (E-C) coupling and for basal metabolism. [20–22,27,29]

The VO2-PVA relationship usually shifts upward or downward in a parallel manner with an increase or decrease in Emax, respectively (Figure 1(C)). [25–27] When Emaxincreases or decreases at a constant LV volume, a VO2-PVA point deviates upward or downward from the baseline VO2-PVA relationship and forms a new steeper VO2-PVA relationship, which traverses multiple parallel VO sub 2 -PVA relationships for different contractilities (Emax). We called this steeper relationship the composite VO2-PVA relationship. [20–22,29] In this relationship, the PVA-independent VO2of the data point increases or decreases in proportion to an increase or decrease in Emax, respectively. The slope (c) of the relation between PVA-independent VO2and Emaxmeans the oxygen cost of Emax, and the intercept (d) of this relationship indicates the PVA-independent VO2extrapolated to zero Emax(Figure 1(D)). [20–22,29] These features of the framework of the Emax-PVA-VO2relationship have been thoroughly reviewed. [20–22] We for the first time applied this mechanoenergetic framework to fentanyl.

Surgical Preparation 

All procedures in this study conformed to US Institutional and National Institutes of Health animal care guidelines. Experiments were performed in six LVs of the excised cross-circulated canine heart preparation that have consistently been used in our laboratory. [31] The surgical procedure has been described in detail elsewhere. [25–27] Briefly, a pair of mongrel dogs (6–25 kg) were anesthetized with pentobarbital (30 mg/kg, intravenous) after the premedication with ketamine (10 mg/kg, intramuscular) and atropine (0.25 mg per dog, intramuscular), intubated, and ventilated artificially with room air. Anesthesia was stably maintained throughout the experiment. If necessary, we administered additional pentobarbital (< 5 mg/kg, intravenous) and had an enough interval for data acquisition (see Discussion section). The blood of each dog was heparinized (at least 10,000 U per dog).

In each experiment, the larger dog was used as the metabolic supporter for the excised heart from the smaller dog. The chest of the donor (smaller) dog was opened midsternally during artificial ventilation. Cross-circulation tubes were cannulated into the bilateral common carotid arteries and unilateral jugular vein of the support dog and connected to the left subclavian artery and the right ventricle (RV) via the right auricle of the donor dog, respectively. The donor heart was isolated from the systemic and pulmonary circulation by ligating the descending aorta, inferior vena cava, azygos vein, brachiocephalic artery, superior vena cava, and bilateral pulmonary hilli in this order. The heart was excised without interruption of coronary perfusion.

The left atrium of the excised heart was widely opened, and all LV chordae tendineae were cut. A thin rubber balloon (an unstressed volume, approximately 50 ml) was fitted into the LV. The excised heart was placed in a box, and temperature of the heart was monitored and maintained at 35–37 degrees Celsius by warming the arterial tube and heating this box. The balloon was connected to our custom-made volume servo pump system (Air-Brown, Tokyo, Japan) and filled with water. This servo-pump system enabled us to control precisely and measure accurately LV volume. LV pressure was measured with a miniature pressure gauge (model P-7, Konigsberg Instruments, Pasadena, CA) placed inside the apical end of the balloon. LV volume and pressure signals were recorded on a strip-chart recorder and stored and processed with a signal-processing computer (7T18, NEC San-ei, Tokyo, Japan). LV epicardial electrocardiogram (ECG) was recorded by a pair of screw-in electrodes to trigger volume control with the servo pump and data acquisition with the processor. The left atrium was paced by a pair of clip electrodes to keep heart rate constant throughout each experiment (136 +/- 15 beats/min; mean +/- SD), approximately 20% above a spontaneous sinus rate to avoid arrhythmia.

Mean systemic arterial blood pressure of the support dog (112.0 +/- 4.4 mmHg), which served as mean coronary perfusion pressure of the excised heart, was monitored in the arterial tube from the bilateral common carotid arteries. We maintained the perfusion pressure above 80 mmHg by primarily transfusing whole blood from the donor dog and additionally hydroxyethyl starch solution (Hespander(R)), 6%, as needed.

Arterial blood gases were repeatedly analyzed with a blood gas analyzer (ABL 330 Acid-Base Laboratory, Radiometer, Copenhagen, Denmark). At the beginning of data sampling, arterial blood gases were adjusted as follows: pH = 7.41 +/- 0.02; PO2= 129.9 +/- 19.1 mmHg; PCO2= 36.4 +/- 3.3 mmHg; and base excess =-1.1 +/- 1.9 mM). They were maintained within their physiologic ranges by adjusting artificial ventilation of the support dog and intravenous administrations of sodium bicarbonate as needed.

At the end of every experiment, we measured the weight of LV (54.2 +/- 17.0 g), including the septum, and RV free wall (23.8 +/- 6.6 g). The ratio of the RV weight to the biventricular weight was 30.7 +/- 4.0%. These LV and RV weights were used to normalize EmaxPVA, and VO sub 2 for 100-g LV weight and to normalize coronary flow (CF) and coronary vascular resistance (CVR) for 100-g biventricular weight, as usual. [20]

Data Samplings and Analyses 

We used isovolumic contractions (shown as arrows in Figure 1(A)) throughout this study. We considered that the contraction mode did not substantially affect the present results because the VO2-PVA relationship is largely independent of the mode of contraction within physiologic loading conditions. [27]

Mechanics. We assessed LV contractility by Emax. P(t) and V(t) data were obtained at 2-ms intervals with the signal processor. In the inotropism run (See Experiment Protocol), we computed Emaxof isovolumic contractions simultaneously at data sampling with the predetermined V0. [23] In each volume loading run (See Experiment Protocol), we determined Eesas the slope of the ESPVR regression line obtained from isovolumic contractions at 4–7 different LV volumes, including V0(Figure 1(A)). [24] LV volume, Emax, and Eeswere normalized for 100-g LV weight and presented in ml/100 g and mmHg [center dot] ml sup -1 [center dot] 100 g, respectively. Note that 100 g, not 100 g sup -1, appears in the unit of Emaxand Ees.

In addition, Tmaxwas determined as the time to Emaxfrom the onset of the R wave of ECG and served as a measure of the duration of systole. [20,23]

Energetics. Pressure-volume Area. We calculated PVA of each LV isovolumic contraction from the digitized P(t) and V(t) data in the same way as before (Figure 1(A)). [20–22,25–27] PVA was normalized for 100-g LV and was presented in mmHg [center dot] ml [center dot] beat sup -1 [center dot] 100 g sup -1.

VO2. We continuously measured coronary arteriovenous oxygen content difference (AVO2D) with a custom-made oximeter (PWA-200S, Shoe Technica Inc., Chiba, Japan). Blood hemoglobin concentration (10.0 +/- 1.6 g/dl) was occasionally measured with a blood O2content analyzer (IL-382 CO-oximeter, Instrumentation Laboratory Inc., Lexington, MA, USA) and was kept high enough (5.0 g/dl) to measure accurate AVO2D. [32,33] CF was also continuously measured with an electromagnetic flow meter (MFV-3200, Nihon Kohden, Tokyo, Japan) placed in the coronary venous drainage tube from the RV (Figure 2). We neglected LV Thebesian flow because of its very small fraction (< 3%) in CF. [20]

Figure 2. Schematic presentation of the experimental setup. LV = left ventricle; LVP = LV pressure; ECG = electrocardiogram; AVO2D= arteriovenous O2content difference; CF = coronary flow.

Figure 2. Schematic presentation of the experimental setup. LV = left ventricle; LVP = LV pressure; ECG = electrocardiogram; AVO2D= arteriovenous O2content difference; CF = coronary flow.

Close modal

Myocardial oxygen consumption of the excised heart per minute was obtained as the product of CF and coronary AVO2D. It was divided by the heart rate to obtain biventricular myocardial oxygen consumption per beat, VO2. RV VO2was minimized by collapsing the RV by continuous hydrostatic drainage of the coronary venous return throughout the experiment and was considered to be constant, regardless of changes in LV PVA. The collapsed RV was assumed to have virtually zero PVA and, hence, no PVA-dependent VO2and biventricular PVA-independent VO2(mechanically unloaded VO2) could be measured at V0. Then, RV PVA-independent VO2was calculated as the product of the biventricular VO2at V0and the ratio of RV weight to the biventricular weight, and this value was subtracted from the total VO2to yield LV VO2. Finally, LV VO2was normalized for 100-g LV and was presented in milliliters of O2[center dot] beat sup -1 [center dot] 100 g sup -1. [27]

VO2-pressure-volume area relationship. In the volume loading run, LV VO2and PVA data were subjected to linear regression analysis to obtain a volume loading VO2-PVA relationship (Figure 1(B)). The equation of the linear VO2-PVA relationship, represented as VO2= a PVA + b, has the following meaningful interpretation: a is the slope of this relationship that represents the oxygen cost of PVA (in milliliters of O2[center dot] mmHg sup -1 [center dot] ml sup -1), a PVA represents the PVA-dependent VO2, and b is the VO2intercept that represents the PVA-independent VO2(unloaded VO2). [20–22,25–27]

In the inotropism run, the oxygen cost of Emaxof fentanyl could be obtained from the composite VO2-PVA relationship if LV contractility (Emax) changes in a dose-dependent manner (Figure 1(C, D)). [20–22,28–30]

Coronary Circulation. Coronary flow was regarded as total biventricular perfusion flow and normalized for 100-g biventricular weight. Coronary perfusion pressure was divided by the normalized CF to yield CVR. CF was presented in ml [center dot] min sup -1 [center dot] 100 g sup -1, and CVR was presented in mmHg [center dot] ml sup -1 [center dot] min [center dot] 100 g.

Experimental Protocol 

The experimental protocol consisted of three runs to be described. Emax, PVA, VO2, and other data were repeatedly measured at least three times to obtain a single set of mean data for each loading and inotropic condition.

1) Control volume loading run: Stable isovolumic contractions were produced at 4–7 different LV volumes including V0between 8.0–44.0 ml/100 g. Peak isovolumic pressure ranged between 0 (at V0) and 189 mmHg.

2) Fentanyl inotropism run: Fentanyl solution (50 micro gram/ml) was diluted to 20 micro gram/ml with 1.5% NaCl to have physiologic osmolarity (0.9% NaCl). Fentanyl was infused into the coronary artery via the cross-circulation tubes through the left subclavial artery with an infusion pump (STC-521, Terumo, Tokyo, Japan; see Figure 2). In two preliminary experiments, we confirmed that intracoronary infusion of saline alone did not affect Emax, PVA, and VO2data at the maximal infusion rate of the pump (2.5 ml/min).

We fixed LV volume at an intermediate level (27.3 +/- 6.1 ml/100 g) where peak isovolumic pressure was 96.1 +/- 22.8 mmHg. The coronary blood fentanyl concentration was increased in steps from 0 (control) to 20, 40, and to 240 ng/ml by increasing the infusion rate. We calculated these concentrations simply by dividing the administration dose by concomitant CF at data sampling and neglected the re-distributed fentanyl in these calculations as in our previous studies. [22,31]

3) Fentanyl volume loading run: When the fentanyl concentration reached 240 ng/ml at the end of fentanyl inotropism run, we finally obtained a set of data at 4–7 different LV volumes in the same way as in the control volume loading run.

Statistics 

The VO2-PVA linear relationships of the control and fentanyl volume runs were compared by analysis of covariance (ANCOVA) in each heart. The significance of the differences in their slopes and elevations was tested by F test. Comparison of control mean values paired with those of fentanyl was performed by Student's paired t test. A value of P < 0.05 was considered statistically significant. All data are presented as mean +/- SD.

In two preliminary experiments, we confirmed that neither Emaxnor the VO2-PVA relationship changed for more than 5 h without any intervention after the onset of cross-circulation, except for transfusions and administration of bicarbonate. Therefore, we performed each experiment within 5 h after the onset of cross-circulation.

(Table 1) shows the data of mechanoenergetics and coronary circulation in the six hearts during the fentanyl inotropism run. None of them were significantly changed by fentanyl at any coronary blood concentrations.

Table 1. Effects of Fentanyl on Left Ventricular Mechanoenergetics and Coronary Circulation in Fentanyl Inotropism Run 

Table 1. Effects of Fentanyl on Left Ventricular Mechanoenergetics and Coronary Circulation in Fentanyl Inotropism Run 
Table 1. Effects of Fentanyl on Left Ventricular Mechanoenergetics and Coronary Circulation in Fentanyl Inotropism Run 

(Table 2) compares a pair of regression lines in the control and fentanyl (240 ng/ml) volume loading runs in each heart; the slope (E sub es) of the ESPVR, the slope and the VO2-axis intercept of the VO sub 2 -PVA relationship, and correlation coefficient (r) are shown. All ESPVRs and VO2-PVA relationships in the control and fentanyl volume loading runs had high and linear correlation; correlation coefficient was always nearly equal to 1.000.

Table 2. Effects of Fentanyl on Left Ventricular Mechanoenergetics in Volume Loading Run 

Table 2. Effects of Fentanyl on Left Ventricular Mechanoenergetics in Volume Loading Run 
Table 2. Effects of Fentanyl on Left Ventricular Mechanoenergetics in Volume Loading Run 

Mechanics 

In the fentanyl inotropism run, Emaxnever decreased significantly at any concentrations at least up to 240 ng/ml in any heart (Table 1).

Between the control and fentanyl volume loading runs in each heart, the ESPVR and its slope were the same (Table 2). Figure 3(A) shows representative data of ESPVRs (experiment 6). These ESPVRs are virtually superimposable. In any of all the six hearts, the mean values of Eesshowed no significant difference by Student's t test (Table 2). These results indicate that fentanyl at any concentrations produced virtually no direct inotropic effect on LV in the excised cross-circulated canine heart.

Fentanyl did not significantly change Tmaxis as shown in Table 1and Table 2, indicating that fentanyl did not affect the duration of systole.

Energetics 

Between the control and fentanyl volume loading runs in each heart, neither the slope nor the VO2intercept of the VO2-PVA relationships showed any significant differences by ANCOVA, except the VO sub 2 -PVA intercept in experiment 4 (Table 2). Figure 3(B) shows a representative set of the VO2-PVA relationships (experiment 6). Both VO2-PVA relationships are superimposable. In any of the six hearts, the mean values of neither the slope nor the VO2intercept of the VO sub 2 -PVA relationships showed any significant differences by Student's t test (Table 2). These results indicate that fentanyl did not affect the oxygen cost of PVA and unloaded VO2(Figure 1(B)).

Figure 3. A representative set of data from experiment 6. The thick solid lines (connecting closed circles) and the dashed lines (connecting open squares) indicate the regression lines during the control and fentanyl (240 ng/ml) volume loading runs, respectively. All end-systolic pressure-volume relations (ESPVR) and VO2(oxygen consumption per beat)-PVA (pressure volume area) relationships in the control and fentanyl volume loading runs have high and linear correlation. A pair of ESPVRs (A) and a corresponding pair of VO2-PVA relations (B) are virtually superimposable, respectively. A, Left ventricular ESPVRs in the pressure-volume diagram. The slopes (Ees) of ESPVRs in the control and fentanyl volume loading runs were 10.4 and 9.4 mmHg [center dot] ml sup -1 [center dot] 100 g, respectively. LVP = left ventricular pressure (mmHg); LVV = left ventricular volume (ml/100 g); V0= a left ventricular volume at which isovolumic peak pressure was zero (ml/100 g). LV contractility was not changed by fentanyl. B, Left ventricular VO2-PVA relationships. The slope and the VO2intercept of the VO2-PVA relationships in the control and fentanyl volume loading runs were 1.94 and 1.84 x 10 sup -5 ml O2[center dot] mmHg sup -1 [center dot] ml sup -1, and 0.036 and 0.036 ml O2[center dot] beat sup -1 [center dot] 100 g sup -1, respectively. Neither O2cost of PVA nor unloaded VO2was changed by fentanyl.

Figure 3. A representative set of data from experiment 6. The thick solid lines (connecting closed circles) and the dashed lines (connecting open squares) indicate the regression lines during the control and fentanyl (240 ng/ml) volume loading runs, respectively. All end-systolic pressure-volume relations (ESPVR) and VO2(oxygen consumption per beat)-PVA (pressure volume area) relationships in the control and fentanyl volume loading runs have high and linear correlation. A pair of ESPVRs (A) and a corresponding pair of VO2-PVA relations (B) are virtually superimposable, respectively. A, Left ventricular ESPVRs in the pressure-volume diagram. The slopes (Ees) of ESPVRs in the control and fentanyl volume loading runs were 10.4 and 9.4 mmHg [center dot] ml sup -1 [center dot] 100 g, respectively. LVP = left ventricular pressure (mmHg); LVV = left ventricular volume (ml/100 g); V0= a left ventricular volume at which isovolumic peak pressure was zero (ml/100 g). LV contractility was not changed by fentanyl. B, Left ventricular VO2-PVA relationships. The slope and the VO2intercept of the VO2-PVA relationships in the control and fentanyl volume loading runs were 1.94 and 1.84 x 10 sup -5 ml O2[center dot] mmHg sup -1 [center dot] ml sup -1, and 0.036 and 0.036 ml O2[center dot] beat sup -1 [center dot] 100 g sup -1, respectively. Neither O2cost of PVA nor unloaded VO2was changed by fentanyl.

Close modal

In the fentanyl inotropism run, the VO2-PVA points never deviated from the control point at any concentrations, correspondingly to a constant Emax. Therefore, we could not obtain any composite VO2-PVA relationship for fentanyl. Consequently, the oxygen cost of Emaxwas not applicable to fentanyl (Figure 1(C, D)).

Coronary Circulation 

In the fentanyl inotropism run, AVO2D, CF, and CVR remained unchanged at any concentrations (Table 1). These results indicate that intracoronary fentanyl did not interfere with the coronary circulation.

This is the first study to have assessed the direct effects of fentanyl on LV mechanoenergetics using the framework of the Emax-PVA-VO2relationship. The present results indicate that intracoronary fentanyl has no effects on LV mechanoenergetics. These results are reliable because this mechanoenergetic relationship is practically independent of ventricular loading conditions. [20–22] In contrast to conventional myocardial contractility indexes, such as LV dp/dtmaxand maximal unloaded shortening velocity (Vmax), Emaxand Eesare considered to be less dependent on ventricular loading conditions. [14,20] Although the effects of fentanyl on cardiac mechanics were previously analyzed by using LV dp/dtmax, this index depends on preload, afterload, and heart rate. [12,13,18]

To evaluate LV mechanoenergetics, we adopted the excised cross-circulated (blood-perfused) canine heart preparation. For clinical relevance, the intact in situ whole heart preparation is the most ideal. However, the in situ beating heart includes many complicating factors because it is hardly possible to control various ventricular loading conditions and exclude any extracardiac inotropic interventions other than intracoronary fentanyl. In the present preparation, we could control LV volume directly and measure LV pressure-volume data and myocardial oxygen consumption precisely. [23–33]

Blood Fentanyl Concentration 

The blood maximal fentanyl concentration we used in the present study (240 ng/ml) is relatively higher than that in the usual clinical and experimental dose. During the induction of clinical anesthesia with a bolus injection of fentanyl (30 micro gram/kg, [7] 60 micro gram/kg, [9] and 75 micro gram/kg [3,10]), mean blood fentanyl concentrations range within 20–160 ng/ml. During the maintenance of fentanyl action, 10–40 ng/ml of fentanyl was required to avoid noxious stimuli sufficiently. [3,7,9–11] Further, in dogs and humans, 30 ng/ml of fentanyl was reported to be sufficient for saturating the general opiate receptors and reaching the maximal effects. [15] However, there was another study reporting that the requirements as an analgesic in the dog vary enormously (25–60 ng/ml) and are extremely high in some animals. [34]

Experimental Implications 

In recent cardiac studies, conscious animals are frequently used to avoid any interference of general anesthetics with experimental data. However, certain preparations require general anesthesia for technical and ethical reasons. The present results indicate that the cardiac mechanoenergetic data during fentanyl treatment are highly favorable. We previously reported that pentobarbital widely used in animal studies initially had positive and then negative inotropism over 25 micro gram/ml of coronary blood concentration, suggesting a narrow safety range of blood concentration in terms of the interference with LV mechanoenergetics. [31] Therefore, we consider that fentanyl is more beneficial than pentobarbital for the excised cross-circulated heart preparation to obtain cardiac mechanoenergetic data.

Clinical Implications 

The present results indicate no direct effects of fentanyl on LV mechanoenergetics up to a much higher concentration than the usual clinical dose. In laboratory studies using isolated myocardial preparations, some investigators have reported a marked direct negative inotropic effect of fentanyl. [16,17] However, these studies are often performed during physiologic conditions such as crystaloid-perfusate, low-temperature, and insufficient oxygen supply. Our preparation is blood-perfused, normothermic, and sufficient oxygen supply, but subject is denervated. Therefore, our present results may not be simply applicable to clinical practice. Further, fentanyl is an analgesic and does not provide reliable consciousness. Consequently, it should not be used as a solitary anesthetic in animals or in humans without supplementary hypnotic drugs.

Methodologic Considerations 

Certain methodologic issues in the present study should be discussed. First, the heart preparation required general anesthesia, and any cardiac effects of the general anesthesia with pentobarbital may have affected the present data. A bolus injection of pentobarbital (30 mg [center dot] kg sup -1 ng [center dot] ml sup -1) kg) remained unchanged (P > 0.05) at 20 ng/ml (0.168 +/- 0.176 ng/ml) and 240 ng/ml (0.078 +/- 0.052 ng/ml) of intracoronary fentanyl. The concentration of norepinephrine (control, 0.688 +/- 0.661 ng/ml) also remained unchanged (P > 0.05) at 20 ng/ml (1.443 +/- 1.646 ng/ml) and 240 ng/ml (1.356 +/- 1.622 ng/ml). Therefore, we exclude the possibility that any indirect effects of fentanyl mediated via the support dog's catecholamine may have affected our present data.

Conclusions 

We have clarified the effects of intracoronary fentanyl on LV mechanoenergetics in the excised cross-circulated (blood-perfused) canine hearts using the framework of the Emax-PVA-VO2relationship. The present results indicate that intracoronary fentanyl produces no effects on LV mechanoenergetics for a wide range of blood concentration, which suggests that fentanyl is a better management choice for experimental animals' general anesthesia required in cardiac studies such as the present mechanoenergetic study. Further, we could suggest that fentanyl anesthesia is suitable for the patients whose LV contractility and energy use have little reserve.

The authors thank Professor M. Hirakawa, who chairs the Department of Anesthesiology and Resuscitology, for his partial financial support of the experiments. The authors also thank Drs. H. Matsubara and J. Shimizu for technical support throughout this study.

1.
Stoelting RK, Gibbs PS, Creasser CW, Peterson C: Hemodynamic and ventilatory responses to fentanyl, fentanyl-droperidol, and nitrous oxide in patients with acquired valvular heart disease. Anesthesiology 1975; 42:319-24.
2.
Stanley TH, Webster LR: Anesthetic requirements and cardiovascular effects of fentanyl-oxygen and fentanyl-diazepam-oxygen anesthesia in man. Anesth Analg 1978; 57:411-6.
3.
Lunn JK, Stanley TH, Eisele J, Woodward A: High dose fentanyl anesthesia for coronary artery surgery: Plasma fentanyl concentrations and influence of nitrous oxide on cardiovascular responses. Anesth Analg 1979; 58:390-5.
4.
Waller JL, Hug CC Jr, Nagle DM, Craver JM: Hemodynamic changes during fentanyl-oxygen anesthesia for aortocoronary bypass operation. Anesthesiology 1981; 55:212-7.
5.
Hicks HC, Mowbray AG, Yhap EO: Cardiovascular effects of and catecholamone responses to high dose fentanyl-O sub 2 for induction of anesthesia in patients with ischemic coronary artery disease. Anesth Analg 1981; 60:563-8.
6.
Tomichek RC, Rosow CE, Philbin DM, Moss J, Teplick RS, Schneider RC: Diazepam-fentanyl interaction: Hemodynamic and hormonal effects in coronary artery surgery. Anesth Analg 1983; 62:881-4.
7.
Wynands JE, Wong P, Whalley DG, Sprigge JS, Townsent GE, Patel YC: Oxygen-fentanyl anesthesia in patients with poor left ventricular function: Hemodynamics and plasma fentanyl concentrations. Anesth Analg 1983; 62:476-82.
8.
Stanley TH, Berman L, Green O, Robertson D: Plasma catecholamine and cortisol responses to fentanyl-oxygen anesthesia for coronary-artery operations. Anesthesiology 1980; 53:250-3.
9.
Bovill JG, Sebel PS: Pharmacokinetics of high-dose fentanyl. Br J Anaesth 1980; 52:795-801.
10.
Wynands JE, Townsend GE, Wong P, Whalley DG, Srikant B, Patel YC: Blood pressure response and plasma fentanyl concentrations during high- and very high-dose fentanyl anesthesia for coronary artery surgery. Anesth Analg 1983; 62:661-5.
11.
Wynands JE, Wong P, Townsent GE, Sprigge JS, Whalley DG: Narcotic requirements for intravenous anesthesia. Anesth Analg 1984; 63:101-5.
12.
Ostheimer GW, Shanahan EA, Guyton RA, Daggett WM, Lowenstein E: Effects of fentanyl and droperidol on canine left ventricular performance. Anesthesiology 1975; 42:288-91.
13.
Freye E: Cardiovascular effects of high dosages of fentanyl, meperidine, and naloxon in dogs. Anesth Analg 1974; 53:40-7.
14.
De Hert SG: Study on the effects of six intravenous anesthetic agents on regional ventricular function in dogs (thiopental, etomidate, propofol, fentanyl, sufentanil, alfentanil). Acta Anaesthesiol Belg 1991; 42:3-39.
15.
Arndt JO, Mikat M, Parasher VC: Fentanyl's analgesic, respiratory, and cardiovascular actions in relation to dose and plasma concentration in unanesthetized dogs. Anesthesiology 1984; 61:355-61.
16.
Goldberg AH, Padget CH: Comparative effects of morphine and fentanyl on isolated heart muscle. Anesth Analg 1969; 48:978-82.
17.
Strauer BE: Contractile responses to morphine, piritramide, meperidine, and fentanyl: A comparative study of effects on isolated ventricular myocardium. Anesthesiology 1972; 37:304-10.
18.
Hirsch LJ, Rooney MW, Mathru M, Rao TLK: Effects of fentanyl on coronary blood flow distribution and myocardial oxygen consumption in the dog. J Cardiothorac Vasc Anesth 1993; 7:50-4.
19.
Blaise GA, Witzeling TM, Sill JC, Vinay P, Vanhoutte PM: Fentanyl is devoid of major effects on coronary vasoreactivity and myocardial metabolism in experimental animals. Anesthesiology 1990; 72:535-41.
20.
Suga H: Ventricular energetics. Physiol Rev 1990; 70:247-77.
21.
Takaki M, Namba T, Araki J, Ishioka K, Ito H, Akashi T, Zhao LY, Zhao DD, Liu M, Fujii W, Suga H: How to measure cardiac energy expenditure? Ischemia-reperfusion in Cardiac Surgery. Edited by Piper HM, Preussue CJ. Dordrecht, Kluwer, 1993, pp 403-19.
22.
Takaki M, Matsubara H, Araki J, Zhao LY, Ito H, Yasuhara S, Fujii W, Suga H: Mechanoenergetics of acute failing hearts characterized by oxygen costs of mechanical energy and contractility, New Horizons for Failing Heart Syndrome. Edited by Sasayama S. Tokyo, Springer-Verlag, 1996, 133-64.
23.
Suga H, Sagawa K, Shoukas AA: Load independence of the instantaneous pressure-volume ratio of the canine left ventricle and effects of epinephrine and heart rate on the ratio. Circ Res 1973; 32:314-22.
24.
Sagawa K: The end-systolic pressure-volume relation of the ventricle: Definition, modification and clinical use. Circulation 1981; 63:1223-7.
25.
Suga H, Hisano R, Goto Y, Yamada O, Igarashi Y: Effect of positive inotropic agents on the relation between oxygen consumption and systolic pressure-volume area in canine left ventricle. Circ Res 1983; 53:306-18.
26.
Suga H, Hayashi T, Suehiro S, Hisano R, Shirahata M, Ninomiya I: Equal oxygen consumption rates of isovolumic and ejecting contractions with equal systolic pressure-volume areas in canine left ventricle. Circ Res 1981; 49:1082-91.
27.
Suga H, Igarashi Y, Yamada O, Goto Y: Cardiac oxygen consumption and systolic pressure-volume area. Basic Res Cadiol 1986; 81(suppl 1):39-50.
28.
Burkhoff D, Yue DT, Okikawa RY, Franz MR, Schaefer J, Sagawa K: Influence of ventricular contractility on non-work-related myocardial oxygen consumption. Heart Vessels 1987; 3:66-72.
29.
Ohgoshi Y, Goto Y, Futaki S, Yaku H, Kawaguchi O, Suga H: New method to determine oxygen cost for contractility. Jpn J Physiol 1990; 40:127-38.
30.
Ohgoshi Y, Goto Y, Futaki S, Yaku H, Kawaguchi O, Suga H: Increased oxygen cost of contractility in stunned myocardium of dog. Circ Res 1991; 69:975-88.
31.
Namba T, Takaki M, Araki J, Ishioka K, Suga H: Energetics of the negative and positive inotropism of pentobarbitone sodium in the canine left ventricle. Cardiovasc Res 1994; 28:557-64.
32.
Shepherd AP, Burgar CG: A solid-state arteriovenous oxygen difference analyzer for flowing whole blood. Am J Physiol 1977; 232:H437-40.
33.
Suga H, Futaki S, Ohgoshi Y, Yaku H, Goto Y: Arteriovenous oximeter for O sub 2 content difference, O sub 2 saturations, and hemoglobin content. Am J Physiol 1989; 257:H1712-6.
34.
Bailey PL, Port J, McJames S, Reinersman L, Stanley TH: Is fentanyl anesthetic in the dog? Anesth Analg 1987; 66:542-8.
35.
Manders WT, Vatner SF: Effects of sodium pentobarbital anesthesia on left ventricular function and distribution of cardiac output in dogs, with particular reference to the mechanism for tachycardia. Circ Res 1976; 39:512-7.
36.
Unruh HW, Wang R, Bose D, Mink SN: Does pentobarbital anesthesia depress left ventricular contractility in dogs? Am J Physiol 1991; 261:H700-6.